Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 2/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
| ▸ | MGLL | Q99685 | 3/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.49 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.49 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | LOX | P28300 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | CFD | P00746 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3547391 | 1.00 | PDK2 (0.56) | PDK2HSD11B1MGLLTAS1R3TAS1R1 | |
| SCHEMBL3545565 | 0.86 | HSD11B1 (0.53) | PDK2HSD11B1MGLLTAS1R3TAS1R1 | |
| SCHEMBL3545564 | 0.86 | HSD11B1 (0.53) | PDK2HSD11B1MGLLTAS1R3TAS1R1 | |
| Hydroxyamine SCHEMBL5238636 | 0.85 | HSD11B1 (0.54) | HSD11B1MGLLTAS1R3TAS1R1TAS1R2 | |
| Hydroxyamine SCHEMBL5238639 | 0.85 | HSD11B1 (0.54) | HSD11B1MGLLTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL3546371 | 0.81 | PDK2 (0.55) | PDK2PDE4BPDE4D | |
| SCHEMBL3551107 | 0.81 | PDK2 (0.55) | PDK2PDE4BPDE4D | |
| SCHEMBL3551111 | 0.81 | PDK2 (0.55) | PDK2PDE4BPDE4D | |
| SCHEMBL3546372 | 0.81 | PDK2 (0.55) | PDK2PDE4BPDE4D | |
| SCHEMBL3546501 | 0.80 | PDK2 (0.52) | PDK2LOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691843-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | VICURON HOLDINGS LLC | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | AMDHD2, OGA, ENGASE | PDK2 2445/4885HSD11B1 2141/4885MGLL 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.